Last reviewed · How we verify
Combination Bupropion + NRTs
Bupropion inhibits norepinephrine and dopamine reuptake while nicotine replacement therapies provide exogenous nicotine to reduce withdrawal symptoms, together addressing both the neurochemical and behavioral aspects of tobacco dependence.
Bupropion inhibits norepinephrine and dopamine reuptake while nicotine replacement therapies provide exogenous nicotine to reduce withdrawal symptoms, together addressing both the neurochemical and behavioral aspects of tobacco dependence. Used for Smoking cessation in adults.
At a glance
| Generic name | Combination Bupropion + NRTs |
|---|---|
| Sponsor | Brentwood Biomedical Research Institute |
| Drug class | Antidepressant + nicotine replacement combination |
| Target | Norepinephrine transporter, dopamine transporter; nicotinic acetylcholine receptors |
| Modality | Small molecule |
| Therapeutic area | Addiction Medicine / Smoking Cessation |
| Phase | FDA-approved |
Mechanism of action
Bupropion is an atypical antidepressant that increases dopamine and norepinephrine availability in the brain, reducing cravings and withdrawal symptoms during smoking cessation. Nicotine replacement therapies (NRTs—patches, gum, lozenges, nasal spray, or inhalers) deliver controlled doses of nicotine to satisfy physical dependence while avoiding the harmful combustion products of cigarettes. The combination leverages complementary mechanisms: bupropion addresses mood and motivation while NRT manages acute nicotine withdrawal.
Approved indications
- Smoking cessation in adults
Common side effects
- Insomnia
- Dry mouth
- Nausea
- Headache
- Dizziness
- Seizures (bupropion)
- Skin irritation (NRT patch)
Key clinical trials
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Combination Bupropion + NRTs CI brief — competitive landscape report
- Combination Bupropion + NRTs updates RSS · CI watch RSS
- Brentwood Biomedical Research Institute portfolio CI